Department of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Department of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Anticancer Res. 2023 Nov;43(11):5155-5166. doi: 10.21873/anticanres.16716.
BACKGROUND/AIM: Concomitant chemoradiotherapy (CCRT) with cisplatin is commonly administered after neck dissection in patients with oral squamous cell carcinoma (OSCC) showing extranodal extension (ENE). This study investigated whether the efficacy of CCRT differed depending on the degree of ENE and whether the expression of epithelial cell adhesion molecule (EpCAM) was associated with prognosis.
Patients with OSCC who underwent neck dissection and had histologically proven neck metastasis (pN+) were investigated retrospectively. ENE was divided into ENE minor (ENEmi; <2 mm) and ENE major (ENEma; ≥2 mm). The expression of EpCAM was also immunohistochemically examined using tissues obtained during neck dissection.
One hundred and seventy pN+ cases [ENE(-), n=89; ENEmi, n=23; ENEma, n=58] were included. Multivariate analysis revealed that advanced T stage and ENEma were significantly correlated with poor prognosis. The 5-year disease-specific survival rates in ENE(-), ENEmi, and ENEma groups were 73.7%, 75.5%, and 28.0% respectively. An add-on effect of postoperative CCRT was not seen in the ENEmi group; however, postoperative CCRT improved the survival of patients in the ENEma group. In the ENEma group, the prognosis was significantly worse in EpCAM-positive patients than in EpCAM-negative patients.
Postoperative CCRT may improve prognosis in ENEma cases. EpCAM expression may be a poor prognostic factor in ENEma cases. On the other hand, postoperative CCRT did not have a significant effect on prognosis in ENEmi cases. Among them, although there was no significant difference in the survival rate, postoperative CCRT could be omitted in ENEmi/EpCAM(-) cases.
背景/目的:对于表现出结外侵犯(ENE)的口腔鳞状细胞癌(OSCC)患者,在颈清扫术后常联合顺铂进行放化疗(CCRT)。本研究旨在探讨 CCRT 的疗效是否因 ENE 程度而异,以及上皮细胞黏附分子(EpCAM)的表达是否与预后相关。
回顾性分析了接受颈清扫术且颈淋巴结转移(pN+)经组织学证实的 OSCC 患者。ENE 分为 ENE 轻度(ENEmi;<2mm)和 ENE 重度(ENEma;≥2mm)。使用颈清扫术中获得的组织,还通过免疫组织化学检查 EpCAM 的表达。
共纳入 170 例 pN+病例[ENE(-),n=89;ENEmi,n=23;ENEma,n=58]。多因素分析显示,晚期 T 分期和 ENEma 与预后不良显著相关。ENE(-)、ENEmi 和 ENEma 组的 5 年疾病特异性生存率分别为 73.7%、75.5%和 28.0%。在 ENEmi 组,术后 CCRT 没有附加作用;然而,在 ENEma 组,术后 CCRT 改善了患者的生存。在 ENEma 组,EpCAM 阳性患者的预后明显差于 EpCAM 阴性患者。
术后 CCRT 可能改善 ENEma 病例的预后。EpCAM 表达可能是 ENEma 病例的不良预后因素。另一方面,术后 CCRT 对 ENEmi 病例的预后没有显著影响。在这些病例中,虽然生存率没有显著差异,但在 ENEmi/EpCAM(-)病例中可以省略术后 CCRT。